Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03855228
Other study ID # C94-145
Secondary ID C94-145
Status Completed
Phase Phase 3
First received
Last updated
Start date March 1, 1995
Est. completion date August 7, 1995

Study information

Verified date February 2022
Source Organon and Co
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of mometasone furoate nasal spray (MFNS) with the addition of loratadine vs MFNS alone, loratadine alone, or placebo, in the treatment of patients with seasonal allergic rhinitis.


Recruitment information / eligibility

Status Completed
Enrollment 704
Est. completion date August 7, 1995
Est. primary completion date August 7, 1995
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - 2-year history of seasonal allergic rhinitis - Positive skin test response to a local seasonal allergen (current, or performed in investigator's office within the past year) - Good health and free of any unstable, clinically significant disease, other than allergic rhinitis, that would interfere with the study schedule or evaluation of seasonal allergic rhinitis Exclusion Criteria: - Women who are pregnant or breastfeeding - Women of childbearing potential who are not using an acceptable form of birth control - Significant history of metabolic, cardiovascular, neurologic, hematologic, hepatic, gastrointestinal, cerebrovascular, respiratory, or renal disease, or any other disorder which, in the judgment of the investigator, could interfere with the study, or require treatment which might interfere with the study - Use of any chronic medication which could affect the course of seasonal allergic rhinitis - Asthma requiring chronic use of inhaled or systemic corticosteroids (inhaled bronchodilators are permitted for asthma treatment) - Current or history of frequent, clinically significant sinusitis or chronic purulent postnasal drip - Upper respiratory tract or sinus infection that requires antibiotic therapy within the previous 2 weeks, or a viral upper respiratory infection (URI) within the 7 days prior to Screening - Dependence upon nasal, oral or ocular decongestants, or nasal topical antihistamines, in the opinion of the investigator - Has rhinitis medicamentosa - Evidence of clinically significant nasal candidiasis - Investigational drug use within the previous 30 days - Nasal structural abnormalities, including large nasal polyps and marked septal deviation, that significantly interfere with nasal air flow - Immunotherapy (desensitization therapy), unless on a stable maintenance schedule for at least one month prior to the Screening visit - History of multiple drug allergies, allergy to antihistamines or corticoids - History of psychosis, antagonistic personality, poor motivation, hypochondriasis, or any other emotional or intellectual problems that are likely to limit the validity of consent to participate in the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mometasone furoate nasal spray (MFNS)
Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.
Loratadine
Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
Placebo nasal spray
Daily dose of placebo administered as a nasal spray for 15 days.
Placebo tablet
Daily dose of placebo administered as an oral tablet for 15 days.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Organon and Co

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Total Nasal Symptom Score (Assessed by Participant) Mean change from baseline (CFB), averaged over study days 1-15, is calculated for total nasal symptom scores assessed by participants. Participants scored 4 symptoms (rhinorrhea; nasal stuffiness; nasal itching; sneezing) in diaries on a scale from 0 (none) to 3 (severe). Scores sum to a total nasal symptom score (range: 0-12); higher values indicate greater severity. A decrease in symptom severity is reflected by a negative CFB.
CFB is the 15-day average score minus baseline score. Scores were recorded twice daily, in morning (AM) and night (PM). Average AM/PM scores are first calculated separately, then averaged together to compute the 15-day average score. If diary entries were missing, an average AM or PM score was not calculated. If neither average AM nor PM score was calculated, total 15-day average score was not calculated. Baseline score is an average of the three AM and three PM scores preceding treatment.
Baseline and days 1 through 15 (average of 15 days of treatment)
Primary Change From Baseline in Total Symptom Score (Assessed by Participant) Mean change from baseline (CFB), averaged over study days 1-15, is calculated for total symptom scores assessed by participants. Participants scored 8 symptoms (rhinorrhea; nasal stuffiness; nasal itching; sneezing; itching/burning eyes; tearing/watering eyes; eye redness; and ear/palate itching) in diaries on a scale from 0 (none) to 3 (severe). Scores sum to a total symptom score (range: 0-24); higher values indicate greater severity. A decrease in symptom severity is reflected by a negative CFB.
CFB is the 15-day average score minus baseline score. Scores were recorded twice daily, in morning (AM) and night (PM). Average AM/PM scores are first calculated separately, then averaged together to compute the 15-day average score. If diary entries were missing, an average AM or PM score was not calculated. If neither average AM nor PM score was calculated, total 15-day average score was not calculated. Baseline score is an average of the three AM and three PM scores preceding treatment.
Baseline and days 1 through 15 (average of 15 days of treatment)
Secondary Change From Baseline in Total Nasal Symptom Score on Day 15 (Assessed by Physician) The mean change from baseline on study day 15 was calculated for total nasal symptom scores assessed by physician. Total nasal symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, and sneezing scores. Physician scored each symptom during study visit at baseline and study day 15, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-12 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.
Baseline and study day 15
Secondary Change From Baseline in Total Symptom Score on Day 15 (Assessed by Physician) The mean change from baseline on study day 15 was calculated for total symptom scores assessed by physician. Total symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, sneezing, itching/burning eyes, tearing/watering eyes, redness of the eyes, and itching of the ears or palate scores. Physician scored each symptom during study visit at baseline and study day 15, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-24 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.
Baseline and study day 15
Secondary Change From Baseline in Total Nasal Symptom Score on Day 8 (Assessed by Physician) The mean change from baseline on study day 15 was calculated for total nasal symptom scores assessed by physician. Total nasal symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, and sneezing scores. Physician scored each symptom during study visit at baseline and study day 8, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-12 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.
Baseline and study day 8
Secondary Change From Baseline in Total Symptom Score on Day 8 (Assessed by Physician) The mean change from baseline on study day 8 was calculated for total symptom scores assessed by physician. Total symptom scores are a composite of the following: rhinorrhea, nasal stuffiness (congestion), nasal itching, sneezing, itching/burning eyes, tearing/watering eyes, redness of the eyes, and itching of the ears or palate scores. Physician scored each symptom during study visit at baseline and study day 8, on a scale from 0 (none) to 3 (severe), totaling to a composite score from 0-24 where a higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.
Baseline and study day 8
Secondary Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis (SAR) on Day 15 (Assessed by Physician) The mean change from baseline on study day 15 was calculated for overall condition of rhinitis. Physicians scored participant rhinitis condition during study visit at baseline and study day 15, on a scale from 0 (none) to 3 (severe). A higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.
Baseline and study day 15
Secondary Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis (SAR) on Day 8 (Assessed by Physician) The mean change from baseline on study day 8 was calculated for overall condition of rhinitis. Physicians scored participant rhinitis condition during study visit at baseline and study day 8, on a scale from 0 (none) to 3 (severe). A higher value indicates greater severity.
A negative change from baseline indicates a decrease in symptom severity.
Baseline and study day 8
Secondary Response to Therapy on Day 15 (Assessed by Physician) Mean response to therapy based on the participant's status relative to baseline. Physician scored participant's response on a scale from 1 (complete relief) to 5 (treatment failure) during study visit on study day 15. A higher value indicates weaker response. Study day 15
Secondary Response to Therapy on Day 8 (Assessed by Physician) Mean response to therapy based on the participant's status relative to baseline. Physician scored participant's response on a scale from 1 (complete relief) to 5 (treatment failure) during study visit on study day 8. A higher value indicates weaker response. Study day 8
See also
  Status Clinical Trial Phase
Completed NCT02424539 - A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR) Phase 4
Completed NCT02486159 - The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture N/A
Completed NCT00770315 - Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) Phase 3
Completed NCT00771160 - MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED) Phase 3
Completed NCT00834119 - Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270) Phase 4
Recruiting NCT04435990 - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites Phase 3
Recruiting NCT05177744 - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Recruiting NCT05621356 - Monitoring Allergen Immunotherapy in Allergic Rhinitis
Not yet recruiting NCT06330974 - Allergy, Asthma, and Atopic Eczema in Finland
Completed NCT03758456 - HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human Phase 1
Completed NCT04645979 - A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico
Completed NCT05122143 - Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers N/A
Completed NCT05901532 - Nasal Irrigation With Chinese Herbal Medicine as an Adjunctive Treatment in Allergic Rhinitis Phase 2
Terminated NCT02722083 - Exploratory Study for Allergy Relief Onset Phase 2
Recruiting NCT05656482 - Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients
Recruiting NCT04898283 - Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. Phase 3
Recruiting NCT06436534 - Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis N/A
Recruiting NCT05922176 - Biomarker Screening for Immunotherapy Response Evaluation Using Microneedle Patch in Patients With Allergic Rhinitis
Completed NCT02679105 - Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy Phase 2/Phase 3
Completed NCT01104012 - Validation of Proteomic Analyses for Allergic Asthma and Rhinitis N/A